Futibatinib Approval Expands Options for Patients With FGFR2+ Cholangiocarcinoma
October 19th 2022
The accelerated approval of the FGFR inhibitor futibatinib on September 30, 2022, has expanded options for previously treated adult patients with unresectable, locally advanced, or metastatic intrahepatic cholangiocarcinoma FGFR2 fusions or rearrangements.1